Appetite Suppressants Linked to Low Nutrient Intake in Some People

BMJ Group

Drugs taken to suppress appetite, such as Wegovy and Mounjaro, are associated with inadequate intakes of key nutrients and energy in some people, finds a small exploratory study, published in the open access journal BMJ Nutrition Prevention & Health.

But there's low awareness of this potential side effect among those taking these drugs amid limited nutritional guidance from clinicians, the findings suggest.

Appetite suppressants are effective treatments for obesity and type 2 diabetes, but little is known about their impact on dietary intake, particularly because appetite suppression may reduce overall food consumption and therefore adequate nutritional intake, say the researchers.

To explore this further, they sought feedback from 14 patients (10 private; 4 NHS) prescribed these drugs at one general practice in England and asked them to recall dietary intake over the previous 2 days, using the validated myfood24 diary.

Each participant's average daily intake of 28 nutrients was estimated using sex specific reference nutrient intake (RNI) values from official UK government dietary recommendations.

The researchers separately focused on fibre, iron, vitamin D, potassium, protein and magnesium intake for which a clinically relevant shortfall was defined as below two-thirds of the RNI.

Foods recorded in myfood24 were classified as either ultra-processed (UPF) or not, with UPF intake expressed as the percentage of total energy intake and used as a proxy measure of poor diet quality.

The analysis showed that average daily energy intake was 1231 kcal, equivalent to 58.5% of sex-specific estimated energy requirements. Three people had intakes below 800 kcal/day. Over half the group consumed less than two-thirds of their estimated requirement.

Of the 28 nutrients assessed, average intakes were below two-thirds of the RNI in 10 people. Protein intake, however, exceeded the RNI, reaching an average of 153%; only one participant's consumption fell below the recommended intake.

More than three quarters of participants were below two-thirds of the RNI for both fibre and vitamin D, while iron intake was below the recommended threshold in half of them.

In all, 8 participants were below two-thirds of the RNI for three or more of the six focus nutrients; one participant fell short across all six. Fruit and vegetable intake fell below the recommended 400g (5-a-day) in all 14.

Average energy-weighted UPF intake was 33% of the total, although the range was wide. One participant derived most (84%) energy from UPFs.

Participant feedback consistently linked reduced nutrient and energy intake to appetite suppression.

Many of the participants described a lack of structured follow-up to monitor progress and address any concerns. And inadequate medication reviews resulted in unmanaged side effects, such as dizziness and low blood pressure, often requiring that person to adjust their medication schedule or seek advice in online peer groups.

"This highlighted a broader gap in professional oversight and safe integration of weight reduction treatments with existing medications," note the researchers.

While many of the interviewees reported reduced 'food noise' and the ability to enjoy food guilt-free, they also reported avoidance of social eating due to nausea or diarrhoea, fears of weight regain on discontinuing treatment, and anxiety about long term affordability.

Unintended consequences of taking these drugs included unexpected reductions in alcohol intake, reduced pleasure from food, and a lack of clear dietary guidance to support safe long term use.

Two people expressed shock and worry at the extent of their reduced calorie intake, which they hadn't realised until filling in the myfood24 diary—something that wouldn't get picked up without some form of monitoring, suggest the researchers.

"Current UK dietary advice is based on the Eatwell Guide, a weight-neutral guide not designed for people with malnutrition in obesity or those on incretin-based therapies [appetite suppressants]. No drug-specific nutritional monitoring framework exists," they highlight.

"The dominance of privately prescribed participants in this cohort suggests that nutritional safety netting may be particularly sparse outside NHS pathways," they add.

This is an observational study, and as such, no conclusions can be drawn about cause and effect. And the researchers acknowledge the small size of their study, and that participants came from one general practice in a relatively affluent area, so the findings may not be widely applicable elsewhere.

But they nevertheless conclude: "This exploratory service evaluation suggests that some patients prescribed [appetite suppressant] therapies may consume very low energy diets and fall short of key micronutrient targets despite adequate protein intake.

"Qualitative findings indicate that appetite suppression can lead to unrecognised reductions in food intake in the absence of structured dietary guidance. Although hypothesis-generating, these observations highlight potential gaps in nutritional monitoring within current incretin therapy care pathways."

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.